Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli.
Open Access
- 1 October 1994
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 269 (43) , 26830-26835
- https://doi.org/10.1016/s0021-9258(18)47094-9
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Structural Heterogeneity of Caucasian N-Acetyltransferase at the NAT1 Gene LocusArchives of Biochemistry and Biophysics, 1993
- Molecular genetics of the N-acetyltransferasesPharmacogenetics, 1993
- SHORT COMMUNICATION: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-AmericansCarcinogenesis: Integrative Cancer Research, 1993
- Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferasesCarcinogenesis: Integrative Cancer Research, 1993
- N-acetyltransferase polymorphism: Comparison of phenotype and genotype in humansBiochemical Pharmacology, 1991
- Diverse point mutations in the human gene for polymorphic N-acetyltransferase.Proceedings of the National Academy of Sciences, 1991
- Molecular mechanism of slow acetylation of drugs and carcinogens in humans.Proceedings of the National Academy of Sciences, 1991
- Human ArylamineN-Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional ExpressionDNA and Cell Biology, 1990
- Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.Journal of Clinical Investigation, 1990
- N-acetyltransferasePharmacology & Therapeutics, 1989